Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration

Conclusion: Macular atrophy developed in about 10% of eyes with neovascular age-related macular degeneration during 12 months of treatment with a fixed regimen of aflibercept. Intraretinal fluid and subfoveal choroidal thickness seem to be predictors for development of macular atrophy after anti-vascular endothelial growth factor (VEGF) therapy.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research